Summit Therapeutics to Present at the Rodman & Renshaw 20th Annual Global Investment Conference
Summit Therapeutics plc
Aug. 29, 2018
OXFORD, United Kingdom and CAMBRIDGE, Mass., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that Mr Glyn Edwards, Chief Executive Officer, will present on the Company’s plans to advance its new mechanism antibiotic pipeline at the Rodman & Renshaw 20th Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, 6 September 2018 at 11:15am EDT in New York City.
A live webcast of the presentation will be available in the Investors section of the Company's website, www.summitplc.com. A replay of the webcast will be available from the same location soon after the live presentation.
About Summit TherapeuticsSummit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for C. difficile infection and gonorrhoea and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.
For more information, please contact: Summit Glyn Edwards/Richard Pye (UK office) Tel: 44 (0)1235 443 951 Erik Ostrowski / Michelle Avery (US office) +1 617 225 4455 Cairn Financial Advisers LLP(Nominated Adviser) Tel: +44 (0)20 7213 0880 Liam Murray / Tony Rawlinson N+1 Singer(Joint Broker) Tel: +44 (0)20 7496 3000 Aubrey Powell / Jen Boorer Panmure Gordon (Joint Broker) Tel: +44 (0)20 7886 2500 Freddy Crossley, Corporate Finance James Stearns, Corporate Broking MSL Group (US) Tel: +1 617 684 6557 Jon Siegal Jon.firstname.lastname@example.org Consilium Strategic Communications(UK) Tel: +44 (0)20 3709 5700 Mary-Jane Elliott / Jessica Hodgson email@example.com / Lindsey Neville